|
Status |
Public on Feb 27, 2018 |
Title |
22RV1 |
Sample type |
SRA |
|
|
Source name |
22RV1_parental
|
Organism |
Homo sapiens |
Characteristics |
tissue: prostate cell line: 22RV1 treatment: control cells
|
Treatment protocol |
22RV1 and LNcaP prostate cancer cells were cultured in RPMI1640 (Gibco) supplemented with 10% (v/v) FBS (Gibco). BETi (JQ1) resistant lines were developed by culturing in above mentioned media with IC50 concentration of the drug (100nM and 200nM for LNcaP and 22RV1 respectively) for over a period of 14-16 weeks.
|
Growth protocol |
Cells were grown in RPMI containing 10% FBS
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was isolated using miRNeasy Kit (Invitrogen) following the manufacturer’s instructions. RNA libraries were prepared for sequencing using standard Illumina protocols
|
|
|
Library strategy |
RNA-Seq |
Library source |
transcriptomic |
Library selection |
cDNA |
Instrument model |
Illumina NextSeq 500 |
|
|
Data processing |
Illumina Nextseq500 reads were trimmed and clipped for quality control. Read quality was checked for each sample using FastQC. Alignment of reads were performed using STAR aligner with the default setting in Illumina Basespace (https:// basespace.illumina.com/home/indexIllumina) Genome_build: hg19 Supplementary_files_format_and_content: FPKM values for each sample
|
|
|
Submission date |
Aug 24, 2017 |
Last update date |
May 15, 2019 |
Contact name |
Irfan A Asangani |
E-mail(s) |
asangani@mail.med.upenn.edu
|
Organization name |
University of Pennsylvania
|
Department |
Cancer Biology
|
Lab |
Asangani
|
Street address |
421 Curie Blvd
|
City |
Philadelphia |
State/province |
Pennylvania |
ZIP/Postal code |
19104 |
Country |
USA |
|
|
Platform ID |
GPL18573 |
Series (1) |
GSE103082 |
Resistance to BET inhibitor leads to new therapeutic vulnerabilities in castration resistant prostate cancer |
|
Relations |
SRA |
SRX3131036 |
BioSample |
SAMN07559489 |